Clinical Trial News
Data Addressing Patient And Physician Barriers To Clinical Trials To Be Presented By Experts
Researchers from University Hospitals Case Medical Center's
(UHCMC) Seidman Cancer Center in Cleveland, OH, will present
findings from two studies evaluating new technologies designed to
address common barriers to patient enrollment in clinical
trials...
Combination Drug Therapy May Be Best Treatment For Osteoporosis
The combination of two different drugs for osteoporosis was
found to increase bone mineral density (BMD) more than treatment
with either drug alone, according to the results of a small
clinical trial published in The Lancet...
New Mathematical Modeling Approach To Analyzing Colorectal Cancer Clinical Trial Data
Certara™, a leading provider of software and scientific
consulting services to improve productivity and decision-making
from drug discovery through drug development, announced that its
Pharsight Consulting Services has developed a mathematical model of
tumor growth inhibition, which when combined with baseline
prognostic factors, predicts treatment effect with
bevacizumab...
Analysis Shows Cancer Biorepository Speeds Clinical Trials, Drug Development
Researchers at Moffitt Cancer Center say identifying and
selecting participants for phase II cancer clinical trials from a
centralized warehouse of patient-donated biological data expedites
participant accrual, reduces trial size, saves money, and may speed
test drugs through the drug development pipeline...
Lantheus Medical Imaging, Inc., a global leader in
developing, manufacturing and distributing innovative diagnostic
imaging agents, today announced an important milestone for its
Phase 3 flurpiridaz F 18 clinical program. An interim analysis of
the first of two Phase 3 studies has met the criteria for
completion...
Merck And Pfizer Collaborate To Develop New Diabetes Drug
Two pharmaceutical companies - Merck & Co Inc. and Pfizer
Inc. - have just announced that they have partnered up for the
development of the type 2 diabetes drug ertugliflozin
(PF-04971729), an investigational oral sodium glucose cotransporter
(SGLT2) inhibitor...
Sofosbuvir Offers High Cure Rate For Two Hepatitis C Subtypes
Sofosbuvir, a new drug, is offering impressive cure rates for
Hepatitis C patients with two subtypes of the disease - genotypes 2
and 3, according to researchers led by Weill Cornell Medical
College. Approximately 1 in every 4 hepatitis C patients in the USA
has one of these two subtypes...
Patient Asks Why Drug Companies Are "Trying To Prevent Disclosure Of Trial Data"
A personal view from a patient with a potentially
life-limiting illness published this week on bmj.com asks why
pharmaceutical giants are trying to prevent the disclosure of trial
data...
